Role of coagulation inhibitors in inflammation

被引:0
作者
Esmon, CT
机构
[1] Univ Oklahoma, Cardiovasc Biol Res Program, Oklahoma Med Res Fdn, Hlth Sci Ctr,Dept Pathol, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Med Res Fdn,Cardiovasc Biol Res Program, Oklahoma City, OK 73190 USA
关键词
thrombin; natural anticoagulants; inflammation; sepsis; endothelium;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is becoming increasingly clear that coagulation augments inflammation and that anticoagulants, particularly natural anticoagulants, can limit the coagulation induced increases in the inflammatory response. The latter control mechanisms appear to involve not only the inhibition of the coagulation proteases, but interactions with the cells that either generate anti-inflammatory substances, such as prostacyclin, or limit cell activation. Recent studies have demonstrated a variety of mechanisms by which coagulation, particularly the generation of thrombin, factor Xa and the tissue factor-factor VIIa complex, can augment acute inflammatory responses. Many of these responses are due to the activation of one or more of the protease activated receptors. Activation of these receptors on endothelium can lead to the expression of adhesion molecules and platelet activating factor, thereby facilitating leukocyte activation. Therefore, anticoagulants that inhibit any of these factors would be expected to dampen the inflammatory response. The three major natural anticoagulant mechanisms seem to exert a further inhibition of these processes by impacting cellular responses. Antithrombin has been shown in vitro to increase prostacyclin responses and activated protein C has been shown to inhibit a variety of cellular responses including endotoxin induced calcium fluxes in monocytes and the nuclear translocation of NF kappaB, a key step in the generation of the inflammatory response. In some, but not all, in vivo models, these natural anticoagulants have been able to inhibit endotoxin/E. coli-mediated leukocyte activation and to diminish cytokine elaboration (TNF, IL-6 and IL-8). Phase III clinical studies for treatment of patients with severe sepsis have been completed for APC, which was successful (1), and for antithrombin, which was not (2). A phase III trial with tissue factor pathway inhibitor is in progress. In this review, the mechanisms by which the different natural anticoagulants are thought to function will be reviewed.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 70 条
  • [1] Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review
    Vincent, JL
    Abraham, E
    Esmon, C
    Hack, CE
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (09) : S33 - S33
  • [2] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [3] REGULATION OF COAGULATION BY A MULTIVALENT KUNITZ-TYPE INHIBITOR
    BROZE, GJ
    GIRARD, TJ
    NOVOTNY, WF
    [J]. BIOCHEMISTRY, 1990, 29 (33) : 7539 - 7546
  • [4] BUSCH C, 1982, LAB INVEST, V47, P498
  • [5] Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
    Camerer, E
    Huang, W
    Coughlin, SR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5255 - 5260
  • [6] Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active
    Camerer, E
    Rottingen, JA
    Iversen, JG
    Prydz, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) : 29034 - 29042
  • [7] Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene
    Camerer, E
    Rottingen, JA
    Gjernes, E
    Larsen, K
    Skartlien, AH
    Iversen, JG
    Prydz, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) : 32225 - 32233
  • [8] ACTIVATION OF PROTEIN-C INVIVO
    COMP, PC
    JACOCKS, RM
    FERRELL, GL
    ESMON, CT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1982, 70 (01) : 127 - 134
  • [9] THROMBIN RECEPTOR FUNCTION AND CARDIOVASCULAR-DISEASE
    COUGHLIN, SR
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 1994, 4 (02) : 77 - 83
  • [10] TISSUE FACTOR PATHWAY INHIBITOR REDUCES MORTALITY FROM ESCHERICHIA-COLI SEPTIC SHOCK
    CREASEY, AA
    CHANG, ACK
    FEIGEN, L
    WUN, TC
    TAYLOR, FB
    HINSHAW, LB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) : 2850 - 2860